CBT Pharma, a US-China company, announced plans to begin an Australian Phase Ib trial of its PD-1 candidate. CBT was founded by CRO CrownBio (TW: 6554), which has supplied CBT with three immuno-oncology candidates, including the PD-1 molecule, known as CBT-501. CBT’s China partner, Genor Biopharma, is responsible for conducting the Australian trials. It plans to test CBT-501 in four separate types of advanced or relapsed/recurrent solid tumors, with each arm enrolling 20 patients.
Source: China Biotoday
